All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
The results of an open-label, multicenter phase II trial on the use of entospletinib in indolent non-Hodgkin lymphoma (iNHL) and mantle cell lymphoma (MCL) were recently published in the British Journal of Haematology, by David Andorsky from the Rocky Mountain Cancer Centers, CO, USA, and colleagues.
Entospletinib (GS-9973) is a competitive inhibitor of the spleen tyrosine kinase (Syk). Syk is actively involved in the B-cell receptor (BCR) signalling pathway as it is believed to act upstream of both the Bruton’s tyrosine kinase (BTK) and phosphoinositide 3-kinase (PI3K). Syk has been associated with lymphoma cell survival and proliferation in many B-cell malignancies and thus provides a great pharmacological target. The aim of this phase II trial (NCT01799889) was to assess the efficacy and tolerability of entospletinib in relapsed or refractory (R/R) iNHL or MCL patients. The primary endpoint of the study was progression-free survival (PFS), as assessed by an independent review committee (IRC). Key secondary endpoints included safety and overall response rate (ORR).
The results of this phase II trial indicate that entospletinib monotherapy leads to low response rates in R/R iNHL and MCL patients, despite its tolerable profile. The investigators proposed that entospletinib should be investigated in combination with other pharmacological agents in patients with hematological malignancies.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Ublituximab and umbralisib for R/R B-cell NHL and CLL/SLL
Results of a phase I/Ib study (NCT02006485) to evaluate the safety and efficacy of U2, in patients with R/R B-cell NHL and CLL/SLL
FDA approves rituximab-pvvr, a rituximab biosimilar, for the treatment of patients with CD20-positive NHL and CLL
On 23 July 2019, the FDA approved rituximab-pvvr, a monoclonal antibody biosimilar to rituximab, for multiple indications in patients...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox